

Natevba® is a prescription medicine indicated for the first-line treatment of X-antigen-positive (XA+) non-Hodgkin's lymphoma¹


An innovative new treatment targeting X-antigen



A breakthrough in precision targeting

Natevba is the only treatment to target X-antigen, a highly specific marker of malignant lymphocytes

Precision targeting ensures minimal toxicity

 More tolerable than chemotherapy^{1,2}

- Lower incidence of Grade 3–4 AEs than chemotherapy
- Low incidence of hematological AEs, including neutropenia
- AEs are generally reversible with appropriate dose adjustments

Precision targeting delivers exceptional results



Over 2 years median PFS²

- 25.2 months with Natevba® vs 14.0 months with chemotherapy
- 45% reduction in risk of progression (HR=0.55, 95% CI: 0.46–0.57)



AE = adverse event; CI = confidence interval; HR = hazard ratio; PFS = progression-free survival; XA+ = X-antigen-positive.

1. Natevba® (vevasumab) Prescribing Information. Lyndhurst, NJ: Verteo 2025

2. Vincent A et al. *Cancer Therapy and Management*. 2020;22(1):87–88.

XA+ NHL is a fictional subtype of a real disease. All content shown here, including claims, data and references, is fictional and intended to represent a hypothetical clinical scenario.